

Interleukin-6 Receptor Antagonists in Critically Ill Patients

New England Journal of Medicine

385, 1147-1149

DOI: [10.1056/nejmc2108482](https://doi.org/10.1056/nejmc2108482)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Review of the pathogenesis, clinical manifestations and peculiarities of neuropsychic disorders caused by COVID-19. Psychiatry Neurology and Medical Psychology, 2021, .	0.1	0
2	A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. ELife, 2021, 10, .	6.0	23
3	Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab. Clinical Infectious Diseases, 2022, 74, 1504-1504.	5.8	2
4	SARS-CoV-2 epidemiology, prevention, risk factors, evaluation, diagnosis, management and vaccines. Osteopathic Family Physician, 2021, 13, .	0.1	0
6	Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19). Expert Opinion on Pharmacotherapy, 2022, 23, 623-628.	1.8	5
7	Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series. AIDS Research and Therapy, 2022, 19, 6.	1.7	4
8	A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 <i>trans</i>-Signaling and Cellular Infection with SARS-CoV-2. Journal of Virology, 2022, 96, JVI0162221.	3.4	5
9	A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. , 2022, 4, e0662.		23
10	WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. Journal of General Internal Medicine, 2022, 37, 1980-1987.	2.6	27
11	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nature Communications, 2022, 13, 2583.	12.8	25
12	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. Vaccines, 2022, 10, 919.	4.4	23
13	Levilimab and baricitinib prescribing experience in outpatient COVID-19 patientsâ€™ treatment. Terapevticheskii Arkhiv, 2022, 94, 668-674.	0.8	3
14	An autopsy case of <scp>COVID</scp> â€“19 with a sudden death: Clinicoâ€“pathological comparison. Clinical Case Reports (discontinued), 2022, 10, .	0.5	3
15	Pharmacy students' knowledge and confidence of COVIDâ€“19 following an interactive didactic class. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 1082-1087.	1.0	3
16	COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. Cancers, 2022, 14, 3711.	3.7	6
17	The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. Frontiers in Immunology, 0, 13, .	4.8	14
19	Eosinophil Levels, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio in the Cytokine Storm Period of Patients with COVID-19. International Journal of Clinical Practice, 2022, 2022, 1-6.	1.7	5
20	COVID-19-associated fungal infections. Nature Microbiology, 2022, 7, 1127-1140.	13.3	183

#	ARTICLE	IF	CITATIONS
21	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). Journal of Intensive Medicine, 2022, 2, 199-222.	2.1	3
22	Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial. Journal of Family Medicine and Primary Care, 2022, 11, 4758.	0.9	2
23	COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports. Journal of Clinical Medicine, 2022, 11, 5519.	2.4	12
24	Obesity and coronavirus disease 2019. Journal of Translational Internal Medicine, 2022, 10, 207-218.	2.5	3
26	Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection. Science Advances, 2022, 8, .	10.3	19
27	Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. Lancet Respiratory Medicine, the, 2022, 10, 1119-1128.	10.7	4
28	Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study. Vaccines, 2022, 10, 1786.	4.4	6
29	Pharmacologic therapies of ARDS: From natural herb to nanomedicine. Frontiers in Pharmacology, 0, 13, .	3.5	4
30	Digital Protein Detection in Bulk Solutions. ACS Omega, 2022, 7, 37714-37723.	3.5	1
31	Treatment of severe COVID-19: an evolving paradigm. Expert Opinion on Pharmacotherapy, 2022, 23, 1887-1891.	1.8	5
32	Thrombotic storm in coronavirus disease 2019: from underlying mechanisms to its management. Journal of Medical Microbiology, 2022, 71, .	1.8	3
33	Computational search for potential COVID-19 drugs from ayurvedic medicinal plants to identify potential inhibitors against SARS-CoV-2 targets. Current Computer-Aided Drug Design, 2022, 19, .	1.2	1
34	COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study. Annals of Medicine, 2023, 55, 12-23.	3.8	3
35	A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access. Clinical Pharmacology and Therapeutics, 2023, 113, 518-527.	4.7	5
36	Fire in the belly: A scoping review of the immunopathological mechanisms of acute pancreatitis. Frontiers in Immunology, 0, 13, .	4.8	4
37	Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Pediatric Infectious Disease Journal, 2023, 42, 119-121.	2.0	4
38	Maternal and Fetal Outcome in Pregnant Women With Critical COVID-19 Treated With Tocilizumab in a Tertiary Care Hospital in Dubai. Cureus, 2023, , .	0.5	0
39	TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial. Thorax, 2023, 78, 816-824.	5.6	3

#	ARTICLE	IF	CITATIONS
40	Targeting IL-6 trans-signalling: past, present and future prospects. Nature Reviews Immunology, 2023, 23, 666-681.	22.7	46
41	The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). Journal of Interferon and Cytokine Research, 2023, 43, 147-163.	1.2	7
42	In the SARS-CoV-2 Pandora Pandemic: Can the Stance of Premorbid Intestinal Innate Immune System as Measured by Fecal Adnab-9 Binding of p87:Blood Ferritin, Yielding the FERAD Ratio, Predict COVID-19 Susceptibility and Survival in a Prospective Population Database?. International Journal of Molecular Sciences, 2023, 24, 7536.	4.1	2
43	COVID-19 and Multiorgan Response: The Long-Term Impact. Current Problems in Cardiology, 2023, 48, 101756.	2.4	2
44	Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy. Cells, 2023, 12, 1664.	4.1	3
45	An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature. Scientific Reports, 2023, 13, .	3.3	7
46	Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses. MBio, 0, , .	4.1	0
47	COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs. RMD Open, 2023, 9, e003038.	3.8	2
49	Quality of reporting of adverse events in clinical trials of covid-19 drugs: systematic review. , 2023, 2, e000352.		1
50	Network pharmacology and molecular docking to scientifically validate the potential mechanism of Lonicerae japonicae flos in the clinical treatment of COVID-19. Natural Product Research, 0, , 1-8.	1.8	0
51	Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis. Frontiers in Pharmacology, 0, 14, .	3.5	0
52	Successful Recovery of COVID-19 Associated With Cardiomyopathy in Advanced Breast Cancer Patient With Pulmonary Lymphangitis Carcinomatosis. Clinical Medicine Insights: Case Reports, 2023, 16, .	0.7	0
53	The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, .	1.7	0
54	Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respiratory Medicine,the, 2023, , .	10.7	6
55	Potential marker subset of blood-circulating cytokines on hematopoietic progenitor-to-Th1 pathway in COVID-19. Frontiers in Medicine, 0, 11, .	2.6	0
56	Early pandemic in-hospital outcomes and mortality risk factors in COVID-19 solid organ transplant patients. Baylor University Medical Center Proceedings, 2024, 37, 414-423.	0.5	0